Therapeutic antibodies have been re-engineered as BSAs that target the insulin receptor, TfR, or IGFR RMT systems at the BBB for the treatment of Alzheimer’s disease and Parkinson’s disease. This evidence concerns the gene IGF1R and early-onset autosomal dominant Alzheimer disease.